Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Byetta in type 2 diabetes mellitus
NCT00111540Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2002
- Primary completion
- Sep 2006
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Primary endpoints: glycosylated hemoglobin at Week 78, body weight at Week 78 and 2 more. Started Nov 2002; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00111540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111540.